Navigation Links
Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709

n these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    For further information please contact:

    Arpida

    Dr Khalid Islam,

    President and CEO

    Tel: +41-61-417-96-60


    Harry Welten,

    MBA, CFO and Senior Vice President

    Tel: +41-61-417-96-65


    Paul Verbraeken,

    Head of Corporate Communications

    Tel: +41-61-417-96-83

CONTACT: For further information please contact: Arpida, Dr Khalid Islam,President and CEO, Tel: +41-61-417-96-60, Harry Welten, MBA, CFO and SeniorVice President, Tel: +41-61-417-96-65, Paul Verbraeken, Head of CorporateCommunications, Tel: +41-61-417-96-83

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Arpida adds novel antibiotic AR-2474 to its preclinical pipeline
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Arpida Announces Promising Results First Man Studies With
(Date:10/9/2008)... Day 2008 focuses on the need to protect the eyesi.../ -- Of the 45 million people worldwide who,are bl...s of them could,have avoided their blindness if th...ew the Multimedia News Release, go to:, http://www...ld,s leader in eye care products and equipment, is...
(Date:10/9/2008)...October 9 /- Diamyd Medical... journal, the New England Journal,of Medicine, has...y,s study,of the Diamyd(R) diabetes vaccine for ty...i-bin/prnh/20080314/297194 ), The article is now...nejm.org ) and will be in print on October 30. It ...
(Date:10/8/2008)...rt Institute Pioneers Research That May Offer New ...- Nationally, over 3,000 people are,w... life. Sadly, only half,of those will receive a tr...t Institute (AHI) is paving the way for how to tre...iew the Multimedia News Release, go to:, http://ww...
(Date:10/8/2008)...ngs Confirm Potency of Poly-ICR as Vaccine Adjuvan...enta Biopharmaceuticals,Corporation (TSX: NVN) tod...s using its proprietary Toll-like Receptor 3 agoni... Vaccine Congress 2008 in Lyon, France.,Study resu...djuvant,targeting the Toll-like Receptor 3 (TLR3) ...
Breaking Medicine Technology:ORBIS and Alcon Call Attention to the Aging Eye 2ORBIS and Alcon Call Attention to the Aging Eye 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 2Diamyd(R) Study Published in Prestigious New England Journal of Medicine 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 4Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 1NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 2NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 3NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 4NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 5NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 6NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 7The Scooter Store to Provide Power Mobility Equipment to HealthPlus of Michigan Patients 4616 1The Scooter Store to Provide Power Mobility Equipment to HealthPlus of Michigan Patients 4616 2The Scooter Store to Provide Power Mobility Equipment to HealthPlus of Michigan Patients 4616 3Bayer Issues Additional Guidance to Physicians on Trasylol 28R 29 663 1Bayer Issues Additional Guidance to Physicians on Trasylol 28R 29 663 2Bayer Issues Additional Guidance to Physicians on Trasylol 28R 29 663 3Bayer Issues Additional Guidance to Physicians on Trasylol 28R 29 663 4Bayer Issues Additional Guidance to Physicians on Trasylol 28R 29 663 5Brain Region Tied to Amphetamine Addiction 4613 1Brain Region Tied to Amphetamine Addiction 4613 2
...wswire/ -- Mersana, a,cancer therapeutics company,...es with its lead product candidate, XMT-1001, will...eting of the,American Association of Cancer Resear...s, CA. Full text of the abstracts can be,viewed on...f=,"http://www.aacr.org/">http://www.AACR.org . , ...
...the risk of cancer,returning after surgery for Kit... * Patients receiving placebo in this trial will n...ions planned for use of Glivec as,adjuvant therapy...ary tumor , * Glivec already approved as effective...inoperable Kit-positive GIST , BASEL, Switzerland,...
Other Medicine Technology:Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 3Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 5Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 6
(Date:10/11/2008)... MegaFest International Transcends Cultural D...wswire/ -- South African and,international audienc...national,s electrifying gathering, which for the f...ica., (Photo: http://www.newscom.com/cgi-bin/prn...y festival kicked off with performances by,South A...
(Date:10/10/2008)...likely to develop some form of disease by 20 years... Oct. 10 (HealthDay News) -- Liver transplant pati...neral population, say researchers in Finland. ,... Liver Transplantation , researchers investigated...splant recipients from Helsinki University Central...
(Date:10/10/2008)...Lilly and Company committed to helping people addr...re-FirstCall/ -- In these troubling,economic times...priority,and may feel that they don,t have the mon...ccording to a survey by the National Association o...t 2008:(1), -- Twenty-two percent of Americans sa...
(Date:10/10/2008)...FORD, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Hol...manufacturer and supplier of premium,diagnostics, ...cated to,serving the healthcare needs of women, to...and fiscal 2008 operating results on Tuesday, Nove...ith the release, management will,host a conference...
Breaking Medicine News(10 mins):Health News:Bishop T.D. Jakes Electrifies South Africa 2Health News:Liver Transplant Patients at Higher Cancer Risk 2Health News:Healthcare Resources Available in Difficult Times 2Health News:Healthcare Resources Available in Difficult Times 3Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2
...ty British cruise vessel, Funchal that has been ar...off the West Australian coast, and will host the m...ngers on board have been infected by a contagious ...municable Disease Control, Dr. Paul Van Buynder sa...
...dex as a tool and indicator of diet is being quest...s. High-GI foods, like white bread and potatoes, t...ome studies have suggested that diets heavy in suc...eight gain, diabetes and heart disease. Still, a d...
...radesh, which has been facing the death of a large...ted the authorities, who in turn has started inves... flu. Suraj Damor, the district magistrate of Burh...in poultry farms at Ichhapur village. Other repor...
...l LWT - Food Science and Technology say that consu...imer’s disease. // Ho Jin Heo and Chang Yong Lee ...nd that red cabbage extract could significantly re...deposits that scientists believe attribute to the ...
Other Medicine News:Health News:Bird Flu Fear Grips Madhya Pradesh 2
Barraquer needle holder, curved, delicate.
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Yasargil Spring Hool with Bulldog Clamp, Galea hook.
Extremely fine straight.
Medicine Products: